August 21, 2026 ยท Tags: venom, drug discovery, medicine, pharmacology
The same venom that kills 100,000 people every year from snakebites is also the source of some of our most important drugs. That is not a contradiction. Venom is a chemical library refined by evolution over millions of years, and we are only now learning to read the labels.
From Snake Venom to Your Medicine Cabinet #
The first venom-derived drug, captopril, hit the market in 1981. It came from the venom of the Brazilian pit viper Bothrops jararaca, and it treats high blood pressure by blocking an enzyme called ACE. Today it is one of the most prescribed drugs in the world, and the snake that inspired it has saved far more human lives than it ever took. Other ACE inhibitors like enalapril followed, and the approach turned into a whole class of drugs (Kim et al., Animal Venom in Modern Medicine, 2025).
Since then, 11 venom-derived drugs have been approved by regulators. They come from snakes, cone snails, Gila monsters, leeches, and scorpions. They treat conditions as different as type 2 diabetes (exenatide, from Gila monster saliva), heart attacks (tirofiban and eptifibatide, from viper venoms), and severe chronic pain (ziconotide, from cone snail venom).
What Makes Venom So Good at Making Drugs #
Venom peptides have three properties that small-molecule drugs often lack. They are potent at low doses, they are highly selective about what they bind to, and they are stable in the body. A toxin that evolved to paralyze a fish by targeting a single type of ion channel can, with some engineering, do the same thing to a pain signal in a human spine without hitting other channels and causing side effects.
Ziconotide is the best example. It is a synthetic copy of a peptide from the cone snail Conus magus, and it blocks N-type calcium channels in the spinal cord. It treats severe chronic pain without the respiratory depression or addiction risk of opioids (Bordon et al., From Animal Poisons and Venoms to Medicines, 2020).
The Next Wave: Scorpions, Anemones, and AI #
A scorpion venom peptide called chlorotoxin is the basis of a drug called tozuleristide, which makes brain tumors glow under infrared light so surgeons can see exactly where to cut. It is in late-stage trials for pediatric brain cancer. Another peptide from the Caribbean sea anemone, ShK, is being turned into a treatment for autoimmune diseases like lupus and multiple sclerosis.
The most interesting frontier is antimicrobials. In 2025, researchers used a deep learning model to screen 16,000 venom proteins. They generated 40 million possible peptide sequences and identified 386 that looked like antibiotics. When they tested 58 of them, 53 killed bacteria. Some were active against Acinetobacter baumannii, a priority pathogen that is resistant to nearly everything we have.
Why This Matters #
Venom has been part of medicine for centuries as a folk remedy. The difference now is that we have the tools to understand how each toxin works at the molecular level and the ability to engineer those molecules into safe, effective drugs. With antibiotic resistance killing 5 million people a year and the opioid crisis still unresolved, venom peptides are one of the few untapped resources that can actually deliver new mechanisms of action. Eleven drugs is a start. The next decade will tell us whether it was a warm-up.